IFNG and cancer: IL-12 has been demonstrated to regulate both innate and adaptive immunities in cancer therapy (46), and IFNγ drives PD-L1 expression (47), which correlates to clinical responses to anti-PD-1 and anti-PD-L1 antibody therapy (37).